Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John P Moore

Showing results (121-130 of 320) with videos related to

Pageof 32
Sort By:
Virology|March 2, 2011
Resistance of a human immunodeficiency virus type 1 isolate to a small molecule CCR5 inhibitor can involve sequence changes in both gp120 and gp41Cleo G Anastassopoulou, Thomas J Ketas, Rafael S Depetris, et al.
Journal of Agricultural and Food Chemistry|February 20, 2015
Following the compositional changes of fresh grape skin cell walls during the fermentation process in the presence and absence of maceration enzymesAnscha J J Zietsman, John P Moore, Jonatan U Fangel, et al.
Nature Communications|February 6, 2015
Antibody potency relates to the ability to recognize the closed, pre-fusion form of HIV EnvMiklos Guttman, Albert Cupo, Jean-Philippe Julien, et al.
Journal of Immunology (Baltimore, Md. : 1950)|March 21, 2006
HIV-1 envelope triggers polyclonal Ig class switch recombination through a CD40-independent mechanism involving BAFF and C-type lectin receptorsBing He, Xugang Qiao, Per J Klasse, et al.
The Journal of Antimicrobial Chemotherapy|November 1, 2012
Pharmacokinetics and efficacy of a vaginally administered maraviroc gel in rhesus macaquesR Karl Malcolm, Claire J Forbes, Leslie Geer, et al.
Plos Pathogens|June 5, 2007
Escape of HIV-1 from a small molecule CCR5 inhibitor is not associated with a fitness lossCleo G Anastassopoulou, Andre J Marozsan, Alexandre Matet, et al.
Virology|April 13, 2007
Entry inhibitor-based microbicides are active in vitro against HIV-1 isolates from multiple genetic subtypesThomas J Ketas, Susan M Schader, Juan Zurita, et al.
Virology|November 23, 2007
N-terminal substitutions in HIV-1 gp41 reduce the expression of non-trimeric envelope glycoproteins on the virusAntu K Dey, Kathryn B David, Neelanjana Ray, et al.
Proceedings of the National Academy of Sciences of the United States of America|August 27, 2009
Structural and biological mimicry of protein surface recognition by alpha/beta-peptide foldamersW Seth Horne, Lisa M Johnson, Thomas J Ketas, et al.
The Journal of Infectious Diseases|July 16, 2010
Protection of rhesus macaques from vaginal infection by vaginally delivered maraviroc, an inhibitor of HIV-1 entry via the CCR5 co-receptorRonald S Veazey, Thomas J Ketas, Jason Dufour, et al.
Pageof 32

Showing results (121-130 of 320) with videos related to

Sort By:
Pageof 32
Virology|March 2, 2011
Resistance of a human immunodeficiency virus type 1 isolate to a small molecule CCR5 inhibitor can involve sequence changes in both gp120 and gp41Cleo G Anastassopoulou, Thomas J Ketas, Rafael S Depetris, et al.
Journal of Agricultural and Food Chemistry|February 20, 2015
Following the compositional changes of fresh grape skin cell walls during the fermentation process in the presence and absence of maceration enzymesAnscha J J Zietsman, John P Moore, Jonatan U Fangel, et al.
Nature Communications|February 6, 2015
Antibody potency relates to the ability to recognize the closed, pre-fusion form of HIV EnvMiklos Guttman, Albert Cupo, Jean-Philippe Julien, et al.
Journal of Immunology (Baltimore, Md. : 1950)|March 21, 2006
HIV-1 envelope triggers polyclonal Ig class switch recombination through a CD40-independent mechanism involving BAFF and C-type lectin receptorsBing He, Xugang Qiao, Per J Klasse, et al.
The Journal of Antimicrobial Chemotherapy|November 1, 2012
Pharmacokinetics and efficacy of a vaginally administered maraviroc gel in rhesus macaquesR Karl Malcolm, Claire J Forbes, Leslie Geer, et al.
Plos Pathogens|June 5, 2007
Escape of HIV-1 from a small molecule CCR5 inhibitor is not associated with a fitness lossCleo G Anastassopoulou, Andre J Marozsan, Alexandre Matet, et al.
Virology|April 13, 2007
Entry inhibitor-based microbicides are active in vitro against HIV-1 isolates from multiple genetic subtypesThomas J Ketas, Susan M Schader, Juan Zurita, et al.
Virology|November 23, 2007
N-terminal substitutions in HIV-1 gp41 reduce the expression of non-trimeric envelope glycoproteins on the virusAntu K Dey, Kathryn B David, Neelanjana Ray, et al.
Proceedings of the National Academy of Sciences of the United States of America|August 27, 2009
Structural and biological mimicry of protein surface recognition by alpha/beta-peptide foldamersW Seth Horne, Lisa M Johnson, Thomas J Ketas, et al.
The Journal of Infectious Diseases|July 16, 2010
Protection of rhesus macaques from vaginal infection by vaginally delivered maraviroc, an inhibitor of HIV-1 entry via the CCR5 co-receptorRonald S Veazey, Thomas J Ketas, Jason Dufour, et al.
Pageof 32